Smaller vs. larger lung surgery after immunotherapy and chemotherapy
Part of Cancer clinical trials.
This trial compares two surgical approaches for advanced lung cancer (stage IIA-IIIB) after patients have already received immunotherapy and chemotherapy. Researchers want to see if removing a smaller portion of the lung (sub-lobectomy) works as well as removing an entire lobe (lobectomy), potentially reducing side effects while fighting cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18–74 years old and in good overall health (able to walk and do light activities)
- You have been diagnosed with non-small cell lung cancer (NSCLC) at stage IIA–IIIB, confirmed by tissue sample
- Your cancer is in one lung and has not spread to other lobes or had prior open chest surgery on that side
- You have already completed 2–4 cycles of immunotherapy (PD-1/PD-L1 inhibitor) combined with chemotherapy before enrolling
- Your lung function tests show you can tolerate surgery (FEV1 ≥1.5 liters or DLCO ≥40%)
- The tumor is at least 2 cm away from the main airway, making smaller surgery feasible
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining a tumor-destroying procedure (ablation) with immunotherapy (tislelizumab) and chemotherapy before surgery can improve outcomes for people with stage II-IIIB non-small cell lung cancer. The goal is to shrink the tumor and boost the immune system to fight the cancer more effectively.
This trial compares two ways of removing lymph nodes during lung cancer surgery after you've had pre-surgery immunotherapy and chemotherapy. It aims to see if taking only a few key lymph nodes (instead of all of them) is just as effective and leads to fewer side effects.
This trial compares two types of lung surgery for early-stage non-small cell lung cancer. You may qualify if you have a small tumor (2 cm or less) with specific features on a CT scan. The goal is to see which surgery offers better outcomes.
This study compares two types of lung cancer surgery — removing only the part of the lung with the tumor (segmentectomy) versus removing the entire lobe (lobectomy) — for patients with early-stage lung cancer that is 2-3 cm. The goal is to see if the smaller surgery works just as well while preserving more lung function.
This study compares two types of lung cancer surgery for early-stage tumors: removing only the part of the lung with the tumor (segmentectomy) versus removing the entire lobe (lobectomy). It aims to see if the smaller surgery works just as well and might be easier to recover from.
This study looks at whether doing surgery after immunotherapy (with or without chemo) can be less invasive than originally planned. If your lung cancer shrunk enough after treatment that you might need a smaller surgery than first thought, this trial could help find the best approach.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.